Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthma.
16srRNA
IL-13
neutrophils
peripheral airways
severe asthma
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
11
11
2020
received:
11
05
2020
accepted:
03
12
2020
pubmed:
8
1
2021
medline:
10
8
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
IL-13 is considered an archetypal T2 cytokine central to the clinical disease expression of asthma. The IL-13 response genes, which are upregulated in central airway bronchial epithelial of asthma patients, can be normalized by high-dose inhaled steroid therapy in severe asthma. However, this is not the case within the peripheral airways. We have sought to further understand IL-13 in the peripheral airways in severe asthma through bronchoalveolar analysis. Bronchoalveolar lavage samples were collected from 203 asthmatic and healthy volunteers, including 78 with severe asthma. Inflammatory mediators were measured using a multiple cytokine immunoassay platform. This analysis was replicated in a further 59 volunteers, in whom 16S rRNA analysis of BAL samples was undertaken by terminal restriction fragment length polymorphism. Severe asthma patients with high BAL IL-13, despite treatment with high-dose inhaled corticosteroids, had more severe lung function and significantly higher BAL neutrophil percentages, but not BAL eosinophils than those with normal BAL-13 concentrations. This finding was replicated in the second cohort, which further associated BAL IL-13 and neutrophilia with a greater abundance of potentially pathogenic bacteria in the peripheral airways. Our findings demonstrate a steroid unresponsive source of IL-13 that is associated with BAL neutrophilia and bacterial dysbiosis in severe asthma. Our findings highlight the biological complexity of severe asthma and the importance of a greater understanding of the innate and adaptive immune responses in the peripheral airways in this disease.
Sections du résumé
BACKGROUND
IL-13 is considered an archetypal T2 cytokine central to the clinical disease expression of asthma. The IL-13 response genes, which are upregulated in central airway bronchial epithelial of asthma patients, can be normalized by high-dose inhaled steroid therapy in severe asthma. However, this is not the case within the peripheral airways. We have sought to further understand IL-13 in the peripheral airways in severe asthma through bronchoalveolar analysis.
METHODS
Bronchoalveolar lavage samples were collected from 203 asthmatic and healthy volunteers, including 78 with severe asthma. Inflammatory mediators were measured using a multiple cytokine immunoassay platform. This analysis was replicated in a further 59 volunteers, in whom 16S rRNA analysis of BAL samples was undertaken by terminal restriction fragment length polymorphism.
RESULTS
Severe asthma patients with high BAL IL-13, despite treatment with high-dose inhaled corticosteroids, had more severe lung function and significantly higher BAL neutrophil percentages, but not BAL eosinophils than those with normal BAL-13 concentrations. This finding was replicated in the second cohort, which further associated BAL IL-13 and neutrophilia with a greater abundance of potentially pathogenic bacteria in the peripheral airways.
CONCLUSION
Our findings demonstrate a steroid unresponsive source of IL-13 that is associated with BAL neutrophilia and bacterial dysbiosis in severe asthma. Our findings highlight the biological complexity of severe asthma and the importance of a greater understanding of the innate and adaptive immune responses in the peripheral airways in this disease.
Identifiants
pubmed: 33411348
doi: 10.1111/all.14732
pmc: PMC8629111
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2070-2078Subventions
Organisme : Medical Research Council
ID : G0800766
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0800649
Pays : United Kingdom
Organisme : Medical Research Council UK
ID : G0900453
Organisme : Medical Research Council
ID : G0900453
Pays : United Kingdom
Organisme : Medical Research Council UK
ID : G0800649
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Curr Opin Pulm Med. 2019 Jan;25(1):113-120
pubmed: 30422895
Lancet Respir Med. 2019 May;7(5):402-416
pubmed: 30876830
N Engl J Med. 2013 Jun 27;368(26):2455-66
pubmed: 23688323
Curr Opin Microbiol. 2012 Feb;15(1):78-84
pubmed: 22055570
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Nat Med. 2012 Jan 15;18(2):260-6
pubmed: 22245779
J Clin Microbiol. 2004 Nov;42(11):5176-83
pubmed: 15528712
Immunity. 2020 Feb 18;52(2):241-255
pubmed: 32075727
J Allergy Clin Immunol. 2016 Jul;138(1):61-75
pubmed: 26851968
PLoS One. 2014 Jun 23;9(6):e100645
pubmed: 24955983
Lancet. 2002 Nov 30;360(9347):1715-21
pubmed: 12480423
Thorax. 2015 Apr;70(4):376-8
pubmed: 24917087
J Allergy Clin Immunol. 2008 Mar;121(3):685-91
pubmed: 18328894
Cell Mol Immunol. 2019 Mar;16(3):225-235
pubmed: 30792500
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15858-63
pubmed: 17898169
J Allergy Clin Immunol. 2019 Jul;144(1):267-279.e4
pubmed: 30768990
PLoS One. 2017 Jan 3;12(1):e0168680
pubmed: 28045928
J Allergy Clin Immunol. 2014 Nov;134(5):1175-1186.e7
pubmed: 25042748
Eur Respir J. 2020 Oct 1;56(4):
pubmed: 32366495
Sci Transl Med. 2015 Aug 19;7(301):301ra129
pubmed: 26290411
Cytokine. 2015 Sep;75(1):68-78
pubmed: 26070934
Curr Opin Immunol. 2018 Oct;54:115-122
pubmed: 30015087
Am J Respir Crit Care Med. 2013 Nov 15;188(10):1193-201
pubmed: 24024497
F1000Res. 2016 Dec 23;5:2912
pubmed: 28105328
Qual Life Res. 2015 Mar;24(3):631-9
pubmed: 25201169
Am J Respir Crit Care Med. 2005 Mar 1;171(5):431-9
pubmed: 15563633
Psychol Methods. 2005 Jun;10(2):178-92
pubmed: 15998176
Lancet. 2017 Aug 12;390(10095):659-668
pubmed: 28687413
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
Chest. 2016 May;149(5):1165-72
pubmed: 26836907
Immunity. 2016 Jul 19;45(1):172-84
pubmed: 27438770